Hydroxycinnamic-acid / P53 Cancer Research Results

HCAs, Hydroxycinnamic-acid: Click to Expand ⟱
Features:
Hydroxycinnamic acid compounds (p-coumaric, caffeic acid (CA), ferulic acid) occur most frequently as simple esters with hydroxy carboxylic acids or glucose, while the hydroxybenzoic acid compounds (p-hydroxybenzoic, gallic acid, ellagic acid) are present mainly in the form of glucosides. https://www.sciencedirect.com/topics/chemistry/hydroxycinnamic-acid
Hydroxycinnamic acids (HCAs) are plant-derived phenolic acids (including caffeic, ferulic, p-coumaric, and sinapic acids) with documented antioxidant, anti-inflammatory (NF-κB↓), and context-dependent anticancer effects in cellular and preclinical models. Mechanistic themes include activation of the Nrf2/ARE antioxidant response, suppression of pro-inflammatory and survival pathways (such as NF-κB and PI3K/AKT), modulation of MAPK signaling, and downstream effects on cell-cycle, apoptosis, invasion, and angiogenesis. Oral exposure is influenced by rapid metabolism (phase II conjugates) and food matrix effects, which affects systemic bioavailability and translational relevance. Biological effects vary by specific hydroxycinnamic derivative and its conjugated/esterified form. (Caffeic acid ≠ ferulic acid ≠ sinapic acid)

-Ferulic acid and p‐coumaric acid are naturally occurring hydroxycinnamic acids found in many plant-based foods (such as whole grains, fruits, and vegetables)

CA showed pro-oxidant potential due to its ability to interact with metals like copper, inducing lipid peroxidation and causing DNA damage within tumor cells through either oxidation or covalent adduct formation.

Summary:
-HCAs are classically antioxidant
-Such as caffeic acid, ferulic acid, and sinapic acid (SA)
-May increase sensitivity to chemotherapy
-Bioavailability is problem. Formulation strategies (e.g., liposomal or encapsulated forms) are investigated to improve systemic exposure.
-Propolis has caffeic acid (Caffeic acid (0.639–4.172 mg/g propolis)
-SA at higher concentrations may acts as a potent pro-oxidant agent
-SA may act in collaboration with other chemotherapeutic agents to improve treatment sensitivity. -Co-administration of caffeic acid or CAPE with other anti-tumor compounds (e.g., gallic acid) has shown additive or synergistic effects in selected models
-Combination of caffeic acid and endogenous copper ions can result in oxidative damage
-Ferulic Acid (abundant in whole grains,popcorn): upregulate apoptotic protein and downregulate anti-apoptotic protein.upregulating (BAX), (p53), (CYCS) and downregulating (Bcl-2),

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Nrf2/ARE antioxidant response (Keap1-Nrf2-HO-1) Stress adaptation modulation (context-dependent) Nrf2 ↑; HO-1 & GSH systems ↑ R, G Endogenous antioxidant upshift Hydroxycinnamic acids commonly promote Nrf2 nuclear translocation and elevate antioxidant defense enzymes; this is one of the most consistent in vivo correlates.
2 NF-κB inflammatory transcription NF-κB ↓; pro-inflammatory cytokine programs ↓ (reported) Inflammation tone ↓; protective in injury models R, G Anti-inflammatory signaling Hydroxycinnamic acids are widely reported to reduce NF-κB activity and downstream cytokine expression across inflammation and tumor models.
3 ROS / oxidative stress modulation Oxidative stress ↓ (often); ROS direction variable Oxidative injury ↓ in stress models P, R, G Redox buffering (context-dependent) These acids are generally antioxidant, but in certain cancer models or at higher concentrations they may affect redox dynamics differentially.
4 Cell-cycle checkpoints (Cyclin D1/CDK4/6; checkpoints) Cell-cycle arrest ↑ (reported); Cyclin/CDKs ↓ ↔ G Cytostasis Largely late phenotype outcome linked to signaling changes.
5 Apoptosis (intrinsic/mitochondrial & caspase-linked) Apoptosis ↑; caspase activation ↑ (reported) ↔ (less activation in normal contexts) G Cell death execution Dependent on model and oxidative stress context; not as “direct” as classical mitochondrial toxins.
6 MAPK re-wiring (ERK / JNK / p38) MAPK modulation (context-dependent) ↔ P, R, G Signal reprogramming Directions vary by tissue, stress levels, and derivative; avoid fixed arrows for all MAPKs unless model-specific evidence is provided.
7 PI3K → AKT (± mTOR) survival axis PI3K/AKT modulation (reported) ↔ R, G Survival/growth modulation Often reported as downstream of NF-κB suppression and redox buffering.
8 Invasion / metastasis programs (MMPs / EMT) MMPs ↓; migration-invasion ↓ (reported) ↔ G Anti-invasive phenotype Observed as downstream phenotypes; direction depends on specific hydroxycinnamic acid derivative.
9 Angiogenesis signaling (VEGF & angiogenic outputs) VEGF ↓; angiogenesis markers ↓ (reported) ↔ G Anti-angiogenic support Later phenotype marker; linked to reduced pro-inflammatory and survival signaling.
10 Bioavailability / metabolism constraint (conjugation; food matrix dependence) Systemic exposure variable; rapid conjugation — — Translation constraint Hydroxycinnamic acids are absorbed but rapidly metabolized (phase II conjugates); food matrix alters bioaccessibility and systemic exposure.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/rapid effects; early redox interactions)
  • R: 30 min–3 hr (acute stress-response + transcription signaling shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
P53, P53-Guardian of the Genome: Click to Expand ⟱
Source: TCGA
Type: Proapototic
TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures.
p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress.
TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers.
Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53.
In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein.
Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver.
Scientific Papers found: Click to Expand⟱
1638- HCAs,    Anticancer potential of hydroxycinnamic acids: mechanisms, bioavailability, and therapeutic applications
- Review, Nor, NA
*BioAv↓, Inflam↓, COX2↓, TumCCA↑, ChemoSen↑, RadioS↑, selectivity↑, ROS↑, DNAdam↑, antiOx↑, SOD↑, Catalase↑, GPx↑, GSH↑, NRF2↑, NF-kB↓, Cyc↓, CDK1↑, P21↑, p27↑, P53↑, VEGF↓, MAPK↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   GSH↑, 1,   NRF2↑, 1,   ROS↑, 1,   SOD↑, 1,  

Cell Death ⓘ

MAPK↓, 1,   p27↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↑, 1,  

Cell Cycle & Senescence ⓘ

CDK1↑, 1,   Cyc↓, 1,   P21↑, 1,   TumCCA↑, 1,  

Angiogenesis & Vasculature ⓘ

VEGF↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   Inflam↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   RadioS↑, 1,   selectivity↑, 1,  
Total Targets: 22

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance ⓘ

BioAv↓, 1,  
Total Targets: 1

Scientific Paper Hit Count for: P53, P53-Guardian of the Genome
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:95  Target#:236  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page